RARE Daily

Sanofi Acquires Tidal Therapeutics with Its Innovative mRNA-based Research Platform

April 12, 2021

Rare Daily Staff

Sanofi said it acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells for up to $470 million.

The technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.

“We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population,” said Frank Nestle, global head of research and chief scientific officer at Sanofi. “We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.”

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells. The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties, with the potential for improved safety, outpatient dosing, and repeat dosing.

Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications.

“Teaming up with Sanofi gives us the opportunity to further develop our unique platform,” said Ulrik Nielsen, president and CEO of Tidal Therapeutics, “and rapidly apply it to ultimately help patients across a range of diseases.”

Photo: Ulrik Nielsen, president and CEO of Tidal Therapeutics

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube